Table_1_TRP Channels Interactome as a Novel Therapeutic Target in Breast Cancer.docx (167.45 kB)
Download file

Table_1_TRP Channels Interactome as a Novel Therapeutic Target in Breast Cancer.docx

Download (167.45 kB)
dataset
posted on 2021-06-10, 06:11 authored by María Paz Saldías, Diego Maureira, Octavio Orellana-Serradell, Ian Silva, Boris Lavanderos, Pablo Cruz, Camila Torres, Mónica Cáceres, Oscar Cerda

Breast cancer is one of the most frequent cancer types worldwide and the first cause of cancer-related deaths in women. Although significant therapeutic advances have been achieved with drugs such as tamoxifen and trastuzumab, breast cancer still caused 627,000 deaths in 2018. Since cancer is a multifactorial disease, it has become necessary to develop new molecular therapies that can target several relevant cellular processes at once. Ion channels are versatile regulators of several physiological- and pathophysiological-related mechanisms, including cancer-relevant processes such as tumor progression, apoptosis inhibition, proliferation, migration, invasion, and chemoresistance. Ion channels are the main regulators of cellular functions, conducting ions selectively through a pore-forming structure located in the plasma membrane, protein–protein interactions one of their main regulatory mechanisms. Among the different ion channel families, the Transient Receptor Potential (TRP) family stands out in the context of breast cancer since several members have been proposed as prognostic markers in this pathology. However, only a few approaches exist to block their specific activity during tumoral progress. In this article, we describe several TRP channels that have been involved in breast cancer progress with a particular focus on their binding partners that have also been described as drivers of breast cancer progression. Here, we propose disrupting these interactions as attractive and potential new therapeutic targets for treating this neoplastic disease.

History

References